Please provide your email address to receive an email when new articles are posted on . Risk estimation was based on area under the receiver operating characteristic curve, sensitivity and specificity ...

—Theses investigators found an increased risk for both individual and composite cardiovascular events following exacerbations of COPD, with sustained risk after 1 year regardless of severity. Reviewed ...

Among hospitalized adults with acute exacerbation of COPD, pegtarazimod improved oxygen utilization and inflammatory ...

Patients with acute COPD exacerbations are seen frequently in the emergency department (ED). Acute exacerbations are associated with significant morbidity, mortality and health care expenditures.

Most chronic obstructive pulmonary disease (COPD) exacerbations were observed in those not treated with controller medications, but less than half of patients in the study received controller ...

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic phenotype. Some 20% to 40% of COPD patients have elevated blood eosinophil counts ...

For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs ...

A research team from the LKS Faculty of Medicine at the University of Hong Kong (HKUMed) has highlighted recent advances in understanding and managing COPD, particularly in relation to its ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Witt: I'm so glad ...

Increased pulmonary vascular resistance independently predicts acute exacerbation-related hospitalization in patients with COPD-PH.

NICE now recommends Nucala for both severe asthma and COPD, expanding the drug’s clinical uptake across the UK’s public ...

Researchers found that the risk for moderate or severe COPD exacerbation was lower among those treated with SGLT-2is vs DPP-4is and among those treated with GLP-1 RAs vs DPP-4is. HealthDay News — For ...